ERBB2 and breast carcinoma: The approval in September 1998 of trastuzumab (Herceptin®, Genentech, Inc., South San Francisco, CA, United States) represented the release of the first antibody for the treatment of metastatic breast cancer patients with HER2 (Receptor tyrosine-protein kinase ERBB2, CD340) overexpression and/or gene amplification, which represented a milestone in the treatment of breast cancer.